Cancer Network | Prostate Cancer
392 FOLLOWERS
Authoritative updates for clinicians on prostate cancer treatment, PSA screening, prostatectomy vs surveillance, chemoprevention, and radiation and proton therapy.
Cancer Network | Prostate Cancer
6h ago
Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer ..read more
Cancer Network | Prostate Cancer
6h ago
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy ..read more
Cancer Network | Prostate Cancer
1w ago
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union ..read more
Cancer Network | Prostate Cancer
1M ago
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer ..read more
Cancer Network | Prostate Cancer
1M ago
The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer ..read more
Cancer Network | Prostate Cancer
1M ago
Results from a post hoc sensitivity analysis of the phase 3 ARASENS trial appear to affirm the primary overall survival analysis findings ..read more
Cancer Network | Prostate Cancer
1M ago
Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer ..read more
Cancer Network | Prostate Cancer
1M ago
Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS ..read more
Cancer Network | Prostate Cancer
1M ago
Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer ..read more
Cancer Network | Prostate Cancer
2M ago
FDA Approves FoundationOne CDx for Niraparib/Abiraterone in BRCA+ mCRPC Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD. Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer Oncology Peer Review On-The-Go: Mediterranean Diet’s Association With Localized Prostate Cancer Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy Everythi ..read more